Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methenamine hippurate is a urinary tract antiseptic used for the prophylaxis and long-term suppression of recurrent urinary tract infections (UTIs). It acts as a prodrug; in the acidic environment of the bladder (pH 5.5 or less), methenamine is hydrolyzed into formaldehyde and ammonia. Formaldehyde is a non-specific bactericidal agent that denatures bacterial proteins and nucleic acids, effectively killing most pathogens without the development of resistance. The hippurate salt component helps maintain the necessary acidic pH of the urine. It is typically administered orally and is particularly useful for patients with chronic or recurrent UTIs where long-term antibiotic use is undesirable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methenamine hippurate.